These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 1688340

  • 1. Dopa decarboxylase activity of the living human brain.
    Gjedde A, Reith J, Dyve S, Léger G, Guttman M, Diksic M, Evans A, Kuwabara H.
    Proc Natl Acad Sci U S A; 1991 Apr 01; 88(7):2721-5. PubMed ID: 1688340
    [Abstract] [Full Text] [Related]

  • 2. Human striatal L-dopa decarboxylase activity estimated in vivo using 6-[18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects.
    Kuwabara H, Cumming P, Reith J, Léger G, Diksic M, Evans AC, Gjedde A.
    J Cereb Blood Flow Metab; 1993 Jan 01; 13(1):43-56. PubMed ID: 8417009
    [Abstract] [Full Text] [Related]

  • 3. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease.
    Kuwabara H, Cumming P, Yasuhara Y, Léger GC, Guttman M, Diksic M, Evans AC, Gjedde A.
    J Nucl Med; 1995 Jul 01; 36(7):1226-31. PubMed ID: 7790948
    [Abstract] [Full Text] [Related]

  • 4. Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine.
    Deep P, Dagher A, Sadikot A, Gjedde A, Cumming P.
    Synapse; 1999 Dec 15; 34(4):313-8. PubMed ID: 10529725
    [Abstract] [Full Text] [Related]

  • 5. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.
    Cumming P, Gjedde A.
    Synapse; 1998 May 15; 29(1):37-61. PubMed ID: 9552174
    [Abstract] [Full Text] [Related]

  • 6. Striatal L-dopa decarboxylase activity in Parkinson's disease in vivo: implications for the regulation of dopamine synthesis.
    Gjedde A, Léger GC, Cumming P, Yasuhara Y, Evans AC, Guttman M, Kuwabara H.
    J Neurochem; 1993 Oct 15; 61(4):1538-41. PubMed ID: 8377003
    [Abstract] [Full Text] [Related]

  • 7. Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease.
    Ishikawa T, Dhawan V, Chaly T, Margouleff C, Robeson W, Dahl JR, Mandel F, Spetsieris P, Eidelberg D.
    J Nucl Med; 1996 Feb 15; 37(2):216-22. PubMed ID: 8667047
    [Abstract] [Full Text] [Related]

  • 8. A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.
    Gallagher CL, Christian BT, Holden JE, Dejesus OT, Nickles RJ, Buyan-Dent L, Bendlin BB, Harding SJ, Stone CK, Mueller B, Johnson SC.
    Mov Disord; 2011 Sep 15; 26(11):2032-8. PubMed ID: 21638324
    [Abstract] [Full Text] [Related]

  • 9. Congenital hyperinsulinism: pancreatic [18F]fluoro-L-dihydroxyphenylalanine (DOPA) positron emission tomography and immunohistochemistry study of DOPA decarboxylase and insulin secretion.
    de Lonlay P, Simon-Carre A, Ribeiro MJ, Boddaert N, Giurgea I, Laborde K, Bellanné-Chantelot C, Verkarre V, Polak M, Rahier J, Syrota A, Seidenwurm D, Nihoul-Fékété C, Robert JJ, Brunelle F, Jaubert F.
    J Clin Endocrinol Metab; 2006 Mar 15; 91(3):933-40. PubMed ID: 16403819
    [Abstract] [Full Text] [Related]

  • 10. 6-[18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods.
    Hoshi H, Kuwabara H, Léger G, Cumming P, Guttman M, Gjedde A.
    J Cereb Blood Flow Metab; 1993 Jan 15; 13(1):57-69. PubMed ID: 8417011
    [Abstract] [Full Text] [Related]

  • 11. High midbrain [18F]DOPA accumulation in children with attention deficit hyperactivity disorder.
    Ernst M, Zametkin AJ, Matochik JA, Pascualvaca D, Jons PH, Cohen RM.
    Am J Psychiatry; 1999 Aug 15; 156(8):1209-15. PubMed ID: 10450262
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine.
    Doudet DJ, Chan GL, Jivan S, DeJesus OT, McGeer EG, English C, Ruth TJ, Holden JE.
    J Cereb Blood Flow Metab; 1999 Mar 15; 19(3):278-87. PubMed ID: 10078880
    [Abstract] [Full Text] [Related]

  • 13. (18F) Fluoro-Dopa: a unique gamma emitting substrate for Dopa decarboxylase.
    Firnau G, Garnett ES, Sourkes TL, Missala K.
    Experientia; 1975 Nov 15; 31(11):1254-5. PubMed ID: 1204761
    [No Abstract] [Full Text] [Related]

  • 14. Behavior of fluorinated analogs of L-(3,4-dihydroxyphenyl)alanine and L-threo-(3,4-dihydroxyphenyl)serine as substrates for Dopa decarboxylase.
    Borri Voltattorni C, Bertoldi M, Bianconi S, Deng WP, Wong K, Kim I, Herbert B, Kirk KL.
    Biochem Biophys Res Commun; 2002 Jul 05; 295(1):107-11. PubMed ID: 12083775
    [Abstract] [Full Text] [Related]

  • 15. [18F]fluoro-L-dopa for the in vivo study of intracerebral dopamine.
    Firnau G, Garnett ES, Chirakal R, Sood S, Nahmias C, Schrobilgen G.
    Int J Rad Appl Instrum A; 1986 Jul 05; 37(8):669-75. PubMed ID: 3021668
    [Abstract] [Full Text] [Related]

  • 16. Kinetics of in vitro decarboxylation and the in vivo metabolism of 2-18F- and 6-18F-fluorodopa in the hooded rat.
    Cumming P, Häusser M, Martin WR, Grierson J, Adam MJ, Ruth TJ, McGeer EG.
    Biochem Pharmacol; 1988 Jan 15; 37(2):247-50. PubMed ID: 3124856
    [Abstract] [Full Text] [Related]

  • 17. Monoamine neuron innervation of the normal human brain: an 18F-DOPA PET study.
    Moore RY, Whone AL, McGowan S, Brooks DJ.
    Brain Res; 2003 Aug 29; 982(2):137-45. PubMed ID: 12915249
    [Abstract] [Full Text] [Related]

  • 18. 6-[18F]fluoro-L-dopa uptake and [76Br]bromolisuride binding in the excitotoxically lesioned caudate-putamen of nonhuman primates studied using positron emission tomography.
    Hantraye P, Loc'H C, Maziere B, Khalili-Varasteh M, Crouzel C, Fournier D, Yorke JC, Stulzaft O, Riche D, Isacson O.
    Exp Neurol; 1992 Feb 29; 115(2):218-27. PubMed ID: 1531196
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of partial volume correction on estimates of the influx and cerebral metabolism of 6-[(18)F]fluoro-L-dopa studied with PET in normal control and Parkinson's disease subjects.
    Rousset OG, Deep P, Kuwabara H, Evans AC, Gjedde AH, Cumming P.
    Synapse; 2000 Aug 29; 37(2):81-9. PubMed ID: 10881028
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.